BNTX:NASDAQ
BioNTech SE - ADR
$104.06
arrow_upward
+1.15%(+1.18) 1D
Sep 4, 1:03:06 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$102.78
High
$104.82
Low
$102.32
Mkt. cap
26.14B
Avg. vol.
1.53M
Volume
302.68K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.77
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$102.78
High
$104.82
Low
$102.32
Mkt. cap
26.14B
Avg. vol.
1.53M
Volume
302.68K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.77
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
The Motley Fool
·
18 hours ago
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Yahoo Finance
·
1 day ago
Is BioNTech Stock a No-Brainer Buy on the Dip?
Reuters
·
4 days ago
BioNTech halts mRNA colorectal cancer vaccine trial after safety review
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR